Post
of 15
RGRX Financials Monday, July 14, 2014 11:13:25 PM
RegeneRx Biopharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 29 1,343 1,512 850
Cost of Revenue - - - -
Gross Profit 29 1,343 1,512 850
Operating Expenses
Research and Development 189 1,162 5,067 2,708
Sales, General and Admin. 755 1,022 2,456 3,174
Non-Recurring Items - - - -
Other - - - -
Operating Income (914) (841) (6,012) (5,032)
Income From Continuing Operations
Add'l Income/Expense Items 344 - 4 8
Earnings Before Interest and Tax (570) (841) (6,007) (5,024)
Interest Expense 101 6 - -
Earnings Before Tax (671) (847) (6,007) (5,024)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (671) (847) (6,007) (5,024)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (671) (847) (6,007) (5,024)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (671) (847) (6,007) (5,024)
RegeneRx Biopharmaceuticals, Inc.
Period Ending Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Total Revenue 29 1,343 1,512 850
Cost of Revenue - - - -
Gross Profit 29 1,343 1,512 850
Operating Expenses
Research and Development 189 1,162 5,067 2,708
Sales, General and Admin. 755 1,022 2,456 3,174
Non-Recurring Items - - - -
Other - - - -
Operating Income (914) (841) (6,012) (5,032)
Income From Continuing Operations
Add'l Income/Expense Items 344 - 4 8
Earnings Before Interest and Tax (570) (841) (6,007) (5,024)
Interest Expense 101 6 - -
Earnings Before Tax (671) (847) (6,007) (5,024)
Income Tax - - - -
Minority Interest - - - -
Equity Earnings Unconsolidated Subsidiary - - - -
Net Income Cont. Operations (671) (847) (6,007) (5,024)
Non Recurring Events
Discontinued Operations - - - -
Extraordinary Items - - - -
Effect of Accounting Changes - - - -
Other Items - - - -
Net Income (671) (847) (6,007) (5,024)
Preferred Stock and Other Adjustments - - - -
Net Income Applicable to Common Shareholders (671) (847) (6,007) (5,024)